Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
48 hedge funds and large institutions have $22M invested in Merrimack Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 47 → 48 (+1)
25% less call options, than puts
Call options by funds: $160K | Put options by funds: $214K
26% less capital invested
Capital invested by funds: $29.9M → $22M (-$7.84M)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sepio Capital
Salt Lake City,
Utah
|
+$668K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$591K |
| 3 |
Renaissance Technologies
New York
|
+$136K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$90.6K |
| 5 |
AAM
Azzad Asset Management
Falls Church,
Virginia
|
+$44.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCIA
Campbell & Co Investment Adviser
Baltimore,
Maryland
|
-$111K |
| 2 |
Morgan Stanley
New York
|
-$86.5K |
| 3 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$40K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$25.8K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$18K |
MACK Hedge Fund Activity: Q4 2019 in Review
48 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2019, worth a combined $22M — down 26% from $29.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MACK positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 15 trimmed.
The largest buyer was Sepio Capital, adding an estimated $668K. The largest seller was Campbell & Co Investment Adviser, exiting entirely with an estimated $111K sold.
- 48 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2019, up from 47 in Q3 2019.
- Funds reported $22M of Merrimack Pharmaceuticals, Inc. stock for Q4 2019, down 26% quarter-over-quarter.
- 5 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2019 and 4 closed out, a net change of +1 holder.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2019 was Sepio Capital, an estimated $668K added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2019 was Campbell & Co Investment Adviser, an estimated $111K sold.
Based on aggregated 13F filings for Q4 2019.